[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Achieve Life Sciences Inc (ACHV)

Achieve Life Sciences Inc (ACHV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 657,018
  • Shares Outstanding, K 102,659
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,650 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 2.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 31.91

Options Overview Details

View History
  • Implied Volatility 97.78% (+0.45%)
  • Historical Volatility 68.92%
  • IV Percentile 12%
  • IV Rank 4.08%
  • IV High 656.67% on 03/02/26
  • IV Low 74.01% on 06/02/26
  • Expected Move (DTE 14) 0.09 (1.33%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 241
  • Volume Avg (30-Day) 1,651
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 37,690
  • Open Int (30-Day) 35,038
  • Expected Range 6.32 to 6.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 3
  • High Estimate $-0.14
  • Low Estimate $-0.21
  • Prior Year $-0.37
  • Growth Rate Est. (year over year) +51.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.70 +36.03%
on 06/03/26
7.11 -9.99%
on 07/01/26
+1.37 (+27.24%)
since 06/02/26
3-Month
3.09 +107.12%
on 04/07/26
7.11 -9.99%
on 07/01/26
+3.17 (+98.14%)
since 04/02/26
52-Week
2.02 +217.62%
on 07/07/25
7.11 -9.99%
on 07/01/26
+4.14 (+183.19%)
since 07/02/25

Most Recent Stories

More News
Achieve Life Sciences Joins Russell 2000® Index

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...

ACHV : 6.40 (unch)
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) --...

ACHV : 6.40 (unch)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (“Achieve” or the “Company”) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...

MANE : 129.74 (+0.98%)
TARS : 65.44 (+7.47%)
ACHV : 6.40 (unch)
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52...

ACHV : 6.40 (unch)
Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline...

ACHV : 6.40 (unch)
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...

ACHV : 6.40 (unch)
Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U . S...

ACHV : 6.40 (unch)
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and...

ACHV : 6.40 (unch)
Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of...

ACHV : 6.40 (unch)
Achieve Life Sciences Announces Up to $354 Million Private Placement

$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations,...

ACHV : 6.40 (unch)

Business Summary

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc.,...

See More

Key Turning Points

3rd Resistance Point 7.05
2nd Resistance Point 6.82
1st Resistance Point 6.61
Last Price 6.40
1st Support Level 6.17
2nd Support Level 5.95
3rd Support Level 5.74

See More

52-Week High 7.11
Last Price 6.40
Fibonacci 61.8% 5.16
Fibonacci 50% 4.56
Fibonacci 38.2% 3.96
52-Week Low 2.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.